Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women's healthcare company, today announced the pricing of its underwritten public offering of 5,333,334 shares of its common stock at a public offering price of $3.75 per share....
Toggle Summary Agile Therapeutics Announces Proposed Offering of Common Stock
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women's healthcare company, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering....
Toggle Summary Agile Therapeutics Reports Second Quarter 2017 Financial Results
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA)  Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three and...
Toggle Summary Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017...
Toggle Summary Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla ® , an investigational low-dose combined...
Toggle Summary Agile Therapeutics Reports First Quarter 2017 Financial Results
Cash Expected to Fund Operations into Q2 2018...
Toggle Summary Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017
Newly Reported Bleeding Profile Shows Reduction in Unscheduled Bleeding/Spotting Days...
Toggle Summary Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American...
Toggle Summary Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women's Health
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled " An Update on Hormonal Contraception and The Changing U.S. Population " will be presented by Co-Principal Investigator of the SECURE...
Toggle Summary Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
Confirms Plans to Re-submit New Drug Application for Twirla® by the end of the Second Quarter of 2017...
Shadow